Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aegleio

- PMLiVE

Lilly/Boehringer’s empagliflozin faces US approval delay

FDA cites manufacturing issues with the new diabetes drug

Interview: Christopher Boulton, AstraZeneca

AstraZeneca’s director of UK marketing and medicines access on the company's increased focused on diabetes

- PMLiVE

AZ gets green light for Bydureon pen in US

FDA approval comes after year-long delay

- PMLiVE

Gliptins don’t cause pancreatic cancer say FDA and EMA

Regulators back safety of diabetes medicine class

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

- PMLiVE

Janssen Invokana combination recommended for European approval

Drug adds metformin to the firm's new SGLT2 inhibitor

- PMLiVE

Interview: Phil Southerland, Team Novo Nordisk

The man behind the world's first all-diabetes cycling team

- PMLiVE

FDA to review safety of AZ’s saxagliptin

Diabetes drug linked to heart failure

- PMLiVE

Merck joins biosimilar Lantus race

Will work with Samsung to develop version of Sanofi's diabetes medicine

Sanofi reception

Sanofi sues Lilly over insulin patents

Challenges development of Lantus biosimilar

- PMLiVE

Novo partners with NHS on diabetes care

Danish pharma company will work with King’s Health Partners in South London

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links